Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Cancer Clinical Trial

Official title:

A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02078089
• Other study ID #: IUCRO-0453
• Status: Terminated
• Phase: Phase 1
• First received: February 24, 2014
• Last updated: January 27, 2017
• Start date: March 6, 2014
• Est. completion date: December 11, 2014

Study information

• Verified date: January 2017
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary endpoints are improving pain control, reduce morphine use and improve the quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: December 11, 2014
• Est. primary completion date: December 11, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent and HIPAA authorization for release of personal health information.

•= 18 years old at the time of informed consent

• Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study.

• Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy.

NOTE: Switching patient from current pain regimen to morphine equivalent for at least 1-2 weeks prior to registration for protocol therapy is required.

• Requiring greater than or equal to 180 mg of morphine per day. See Appendix 1 for Morphine Conversion Calculator.

• Inadequately controlled pain even with the use of morphine (VAS score >5) See Appendix 8

• Rescue pain medications are allowed this may include the use of NSAIDS or Tylenol as well as morphine IR.

• ECOG Performance Status of 0-2

• Ability to swallow and tolerate oral tablets.

• Patients getting radiation therapy are allowed at the discretion of the treating physician.

• Females of childbearing potential must have a negative pregnancy test NOTE: Females are considered of child bearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal (> 12 months since last menses).

NOTE: Females using hormonal contraceptives should be switched to non-hormonal forms of contraception.

The following laboratory values must be obtained. Patient with aplastic anemia will be excluded.

• White blood cell count (WBC) = 3.0 K/mm3

• Absolute neutrophil count = 1.5 K/mm3

• Hemoglobin (Hgb) = 9 g/dL

• Platelets = 75 K/mm3

• Creatinine = 1.5 mg/dl

• Bilirubin = 1.5 x ULN

• Aspartate aminotransferase (AST, SGOT) = 3 x ULN

• Alanine aminotransferase (ALT, SGPT) = 3 x ULN

Exclusion Criteria:

• Active central nervous system (CNS) metastases. Patients with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician.

NOTE: Patients with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.

• Concurrent use of adjuvant medication such as but not limited to: gabapentin, pregabalin or duloxetine etc.

NOTE: Patients on gabapentin or pregabalin can be considered if they can be tapered off before enrolling on the study.

• Treatment with any investigational agent within 30 days prior to registration for protocol therapy.

• Patient with rapidly escalating pain that require hospitalization or an intravenous opioid therapy

• Concurrent participation in a clinical trial which involves another investigational agent.

• Concurrent use of medications that are strong CYP3A4 inhibitors within 14 days prior to registration for protocol therapy as Oxcarbazepine is strong CYP3A4 inducer. See Appendix 7.

NOTE: Concurrent use of other CYP3A4 inhibitors may be allowed at the discretion of the treating physician or principal investigator.

• Allergic reaction to carbamazepine or oxcarbazepine (HLA-B1502)

• Allergy or other contraindication to morphine sulphate

• Opiate-induced uncontrolled constipation or bowel obstruction

• Patient who lives alone.

• Female who is pregnant or breastfeeding

• Patient who has a diagnosis of epilepsy and/or is currently taking anti-epileptic drugs

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Morphine
Morphine will be given to patients as part of their standard care
• Oxcarbazepine
Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.

Locations

Country	Name	City	State
United States	Indiana Univeristy Health Hospital	Indianapolis	Indiana
United States	Indiana University Simon Cancer Center	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Costantine Albany

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events as a measure of safety and toxicity	Evaluate the safety and toxicity of oxcarbazepine in combination with morphine	1 year
Secondary	Changes in Pain control	Evaluate changes in pain control after adding oxcarbazepine to morphine	1 year
Secondary	Changes in Consumption	Evaluate changes morphine consumption after adding oxcarbazepine to morphine	1 year
Secondary	Changes in Quality of Life	Evaluate changes in Quality of Life after adding oxcarbazepine to morphine	1 year